Asterias Biotherapeutics Inc Stock price

Equities

AST

US04624N1072

Biotechnology & Medical Research

Delayed Nyse 5-day change 1st Jan Change
- USD -.--% Intraday chart for Asterias Biotherapeutics Inc +3.85% +52.42%
Asterias Biotherapeutics, Inc. is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients' immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient's own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells.
More about the company
  1. Stock
  2. Equities
  3. Stock Asterias Biotherapeutics Inc - Nyse